Job Trends
BioSpace data show job postings live increased quarter over quarter, while layoffs fell year over year.
Labor Market Reports
BioSpace’s 2026 U.S. Life Sciences Employment Outlook examines the state of the biopharma workforce amid ongoing funding pressure, elevated layoffs and cautious hiring sentiment, while highlighting early signals of stabilization and cautious optimism for the year ahead.
BioSpace’s 2025 Q4 U.S. Life Sciences Job Market update highlights early signs of stabilization in biopharma hiring, with modest gains in job postings, slowing layoffs, and cautiously improving sentiment heading into 2026.
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
Now Hiring
Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.
Looking for an IT job? From data engineer to information security, check out the BioSpace list of 10 companies hiring life sciences professionals like you.
More biopharma organizations were actively recruiting at the end of 2025 than 2024, based on the new BioSpace employment outlook report. Areas in demand this year include research and development and clinical. Organizations are also prioritizing artificial intelligence hires.
Career Advice
If workloads aren’t adjusted as needed, the company’s priorities are already compromised. Executive coach Angela Justice explores what happens when goals move forward without removing unnecessary work and what to do about it.
THE LATEST
In 2013 Pfizer launched its Dare to Try initiative, a project designed to foster internal innovation at the pharma giant. It was an effort that encouraged employees to not be afraid to fail as they reached for the sky.
Bio-Path Holdings, Inc. provides an update from several clinical development programs and a 2019 business overview
Neos Therapeutics, Inc. announced that it has entered into a confidential settlement and licensing agreement with Teva Pharmaceuticals USA, Inc. to resolve all ongoing litigation involving Neos’ patents protecting its Cotempla XR-ODT® extended-release orally disintegrating tablets and Teva’s Abbreviated New Drug Application filed with the U.S. Food and Drug Administration to market a generic version of that product.
Companies closed out the year with a number of appointments and hires to strengthen their leadership teams, including changes at the FDA, Melinta, CLSA, Virion, and more.
For the last couple decades, states have shown an interest in boosting the biotech industry. Massachusetts and California are dominant in biotech startups, and recently Texas expressed its hopes of being a great “third coast” for biotech clusters.
After enduring a deluge from multiple hurricanes earlier this year, the Carolinas are about to be flooded with something else far more preferable – jobs. Pharma companies are hiring for hundreds of positions, according to reports.
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved BRACAnalysis CDx® to be used by healthcare professionals to identify patients with advanced ovarian cancer who have a germline BRCA mutation (gBRCAm) and are eligible for first-line maintenance therapy with AstraZeneca’s PARP (poly ADP ribose polymerase) inhibitor, Lynparza®
Paris-based Sanofi signed the lease on two buildings yet to be built in East Cambridge, Massachusetts. Sanofi is the state’s largest life science employer and plans to shift 2,700 staffers into the two buildings at Cambridge Crossing.
With the year closing out, biotech and pharma companies are making adjustments to their leadership ranks and boards of directors.
Orchard Therapeutics is expanding its physical footprint in California. The U.K.-based company signed a long-term lease to build out a gene therapy manufacturing facility in Fremont, Calif. The 150,000-square-foot facility will add to the company’s presence in the Bay Area.